Logo image of OLMA

OLEMA PHARMACEUTICALS INC (OLMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OLMA - US68062P1066 - Common Stock

26 USD
-1.98 (-7.08%)
Last: 12/9/2025, 11:20:08 AM
Fundamental Rating

2

Overall OLMA gets a fundamental rating of 2 out of 10. We evaluated OLMA against 531 industry peers in the Biotechnology industry. OLMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OLMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OLMA has reported negative net income.
OLMA had a negative operating cash flow in the past year.
OLMA had negative earnings in each of the past 5 years.
In the past 5 years OLMA always reported negative operating cash flow.
OLMA Yearly Net Income VS EBIT VS OCF VS FCFOLMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -42.55%, OLMA perfoms like the industry average, outperforming 56.87% of the companies in the same industry.
The Return On Equity of OLMA (-48.77%) is better than 66.48% of its industry peers.
Industry RankSector Rank
ROA -42.55%
ROE -48.77%
ROIC N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
OLMA Yearly ROA, ROE, ROICOLMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OLMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OLMA Yearly Profit, Operating, Gross MarginsOLMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

OLMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OLMA has been increased compared to 5 years ago.
OLMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OLMA Yearly Shares OutstandingOLMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OLMA Yearly Total Debt VS Total AssetsOLMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

OLMA has an Altman-Z score of 26.63. This indicates that OLMA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of OLMA (26.63) is better than 92.66% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that OLMA is not too dependend on debt financing.
OLMA has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 26.63
ROIC/WACCN/A
WACCN/A
OLMA Yearly LT Debt VS Equity VS FCFOLMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

OLMA has a Current Ratio of 8.03. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
OLMA has a Current ratio of 8.03. This is in the better half of the industry: OLMA outperforms 74.01% of its industry peers.
A Quick Ratio of 8.03 indicates that OLMA has no problem at all paying its short term obligations.
OLMA has a better Quick ratio (8.03) than 74.01% of its industry peers.
Industry RankSector Rank
Current Ratio 8.03
Quick Ratio 8.03
OLMA Yearly Current Assets VS Current LiabilitesOLMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.61% over the past year.
EPS 1Y (TTM)14.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OLMA will show a small growth in Earnings Per Share. The EPS will grow by 1.84% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.64%
EPS Next 2Y-5.44%
EPS Next 3Y-3.08%
EPS Next 5Y1.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OLMA Yearly Revenue VS EstimatesOLMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OLMA Yearly EPS VS EstimatesOLMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OLMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OLMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OLMA Price Earnings VS Forward Price EarningsOLMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OLMA Per share dataOLMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

OLMA's earnings are expected to decrease with -3.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.44%
EPS Next 3Y-3.08%

More info and screens

0

5. Dividend

5.1 Amount

OLMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OLEMA PHARMACEUTICALS INC

NASDAQ:OLMA (12/9/2025, 11:20:08 AM)

26

-1.98 (-7.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners89.18%
Inst Owner Change-4.6%
Ins Owners3.61%
Ins Owner Change-4.21%
Market Cap2.05B
Revenue(TTM)N/A
Net Income(TTM)-149.96M
Analysts86.67
Price Target37.23 (43.19%)
Short Float %12.35%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.15%
Min EPS beat(2)-32.98%
Max EPS beat(2)0.67%
EPS beat(4)3
Avg EPS beat(4)5.09%
Min EPS beat(4)-32.98%
Max EPS beat(4)30.8%
EPS beat(8)5
Avg EPS beat(8)2.82%
EPS beat(12)8
Avg EPS beat(12)5.27%
EPS beat(16)10
Avg EPS beat(16)3.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)53.92%
PT rev (3m)50%
EPS NQ rev (1m)-7.4%
EPS NQ rev (3m)-7.6%
EPS NY rev (1m)-3.43%
EPS NY rev (3m)-0.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.65
P/tB 6.65
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-2.46
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS3.91
TBVpS3.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.55%
ROE -48.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.03
Quick Ratio 8.03
Altman-Z 26.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)46.82%
Cap/Depr(5y)345.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.33%
EPS Next Y12.64%
EPS Next 2Y-5.44%
EPS Next 3Y-3.08%
EPS Next 5Y1.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.93%
EBIT Next 3Y-17.31%
EBIT Next 5YN/A
FCF growth 1Y-58.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.49%
OCF growth 3YN/A
OCF growth 5YN/A

OLEMA PHARMACEUTICALS INC / OLMA FAQ

What is the ChartMill fundamental rating of OLEMA PHARMACEUTICALS INC (OLMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OLMA.


Can you provide the valuation status for OLEMA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to OLEMA PHARMACEUTICALS INC (OLMA). This can be considered as Overvalued.


How profitable is OLEMA PHARMACEUTICALS INC (OLMA) stock?

OLEMA PHARMACEUTICALS INC (OLMA) has a profitability rating of 1 / 10.